Data is n and % (95% CI). *Mortality reduction and CI's from hazard ratio weighted by pooled cumulative ovarian cancer mortality. †For the Weibull model shape parameter p = 1·62 (95% CI: 1·51, 1·75) and baseline (log-hazard) rate = -9·56 (95% CI: -9·87, -9·27) [unweighted] and p=3·02 (95% CI: 2·80, 3·23) with baseline (log-hazard) rate = -13·62 (95% CI: -13·17, -14·07) [weighted]
Web GI -Gastro Intestinal. In women who had more than one complication, the most serious was reported.
Web Table 7 Ovarian cancer survival in women with ovarian cancer in the Control group. Overlaid are UKCTOCS 5 and 10 year survival rates (red dash lines) and age-standardized UK population yearly survival rates (pink circles).
Web 
Number at risk (number of OC diagnoses) C MMS USS Standardized mortality ratio estimates (left panel) and standardized incidence ratio estimates (right panel) with 95% confidence limits over time for the Control group. Observed rates have been compared to age-adjusted expected rates based on UK population data. Note, for presentational purposes, the upper-bound for the 13 th year SMR estimate has been capped at 2·2, but is actually 2·88.
Web Figure 11 : Standardized mortality ratio estimates (left panel) and standardized incidence ratio estimates (right panel) with 95% confidence limits over time for the no screening group. Observed rates have been compared to age-adjusted expected rates based on UK population data. Note, for presentational purposes, the upper-bound for the 13th year SMR estimate has been capped at 2·2, but is actually 2·88.
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C. Estimation of CA125 Change-point
To identify the likelihood of a case being prevalent, we used the serial CA125 pattern to estimate whether each cancer's change-point occurred prior to randomisation (T0). The intersection of the baseline CA125 line and the rising CA125 line estimated the change-point (Supplementary Figure 1a) . 1 Cases where the change-point was before T0 were excluded (Supplementary Figure 1b) . This approach provides an objective assessment of which cases are prevalent based on a case's CA125 profile instead of assuming an arbitrary interval of time from T0 to diagnosis to define prevalent cases. To estimate the change-point for ovarian cases in the no screening group, banked baseline serum samples were available in 517 of the 630 women. These were retrieved and CA125 measured in the CC laboratory using the same assay/analyser as during the trial. 105 baseline MMS samples were also re-assayed for CA125 revealing no significant difference due to long term storage between the new result and the measurement at randomisation. The results combined with CA125 at diagnosis in no screening group cases and the distribution of rate of rise from MMS cases were used to estimate change-points for no screening group cases using the same method as for the MMS cases. 1 For the no screening group cases and some MMS cases, there was uncertainty as to whether the change-point occurred after T0 (Supplementary Figure 1c) 
D. Outcomes review
Ascertainment of outcomes involved interrogation of all available data sources to identify women diagnosed postrandomisation with any of 19 ICD-10 codes14 (Supplementary Table1). Copies of medical notes were retrieved for all except women who had an ICD10-C80 (malignant neoplasm of uncertain origin) and also had another specific non ovarian/peritoneal cancer registration. The table below details the proportion of women for whom we were able to provide information to the Outcomes review committee in the form of copies of medical notes in addition to cancer and/or death registration. Excluding women with ICD10-C80 (malignant neoplasm of uncertain origin) who also had another specific non ovarian/peritoneal cancer registration, we were able to provide additional information in 99% (1757/1767) of women with regards to cancer diagnosis and 97% (876/900) with regard to death diagnosis. There was no significant differences in the proportion of women with missing data between the randomisation groups.
Availability of information in addition to cancer and/or death registration 
